cobactan vet. 25 mg/ml injektionsvæske, suspension
intervet international b.v. - cefquinomsulfat - injektionsvæske, suspension - 25 mg/ml - kvæg, svin
cobactan vet. 75 mg/ml injektionsvæske, suspension
intervet international b.v. - cefquinomsulfat - injektionsvæske, suspension - 75 mg/ml - kvæg
cobactan vet. 75 mg intramammær salve
intervet international b.v. - cefquinomsulfat - intramammær salve - 75 mg - kvæg
cobactan vet. 45 mg/ml pulver og solvens til injektionsvæske, opløsning
intervet international b.v. - cefquinomsulfat - pulver og solvens til injektionsvæske, opløsning - 45 mg/ml - hest
cefepim "mip" 1 g pulver til injektions-/infusionsvæske, opløsning
mip pharma gmbh - cefepimdihydrochloridmonohydrat - pulver til injektions-/infusionsvæske, opløsning - 1 g
cefepim "mip" 2 g pulver til injektions-/infusionsvæske, opløsning
mip pharma gmbh - cefepimdihydrochloridmonohydrat - pulver til injektions-/infusionsvæske, opløsning - 2 g
zavicefta
pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibakterielle midler til systemisk brug, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..